Cargando…
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians’ treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from Norway’s two largest regional hospitals. Clinicopathological data from n = 467...
Autores principales: | Blakstad, Hanne, Brekke, Jorunn, Rahman, Mohummad Aminur, Arnesen, Victoria Smith, Miletic, Hrvoje, Brandal, Petter, Lie, Stein Atle, Chekenya, Martha, Goplen, Dorota |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894455/ https://www.ncbi.nlm.nih.gov/pubmed/36730349 http://dx.doi.org/10.1371/journal.pone.0281166 |
Ejemplares similares
-
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
por: Rahman, Mohummad A., et al.
Publicado: (2020) -
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019) -
Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI
por: Hannisdal, Marianne H, et al.
Publicado: (2023) -
P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)
por: Goplen, D, et al.
Publicado: (2021) -
Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway
por: Rahman, Mohummad Aminur, et al.
Publicado: (2022)